<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Daunorubicin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Daunorubicin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Daunorubicin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11335" href="/d/html/11335.html" rel="external">see "Daunorubicin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13207" href="/d/html/13207.html" rel="external">see "Daunorubicin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708684"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Extravasation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:4em;">Daunorubicin must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is extravasation during administration.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">It is recommended that daunorubicin be administered only by physicians who are experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiomyopathy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m<sup>2</sup> in adults, 300 mg/m<sup>2</sup> in children older than 2 years of age, or 10 mg/kg in children younger than 2 years of age.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic impairment:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dosage should be reduced in patients with impaired hepatic function.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Renal impairment:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dosage should be reduced in patients with impaired renal function.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866526"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cerubidine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F157160"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anthracycline;</li>
<li>
                        Antineoplastic Agent, Topoisomerase II Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F157121"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Cumulative doses above 550 mg/m<sup>2</sup> in adults without risk factors for cardiotoxicity and above 400 mg/m<sup>2</sup> in adults receiving chest irradiation are associated with an increased risk of cardiomyopathy (manufacturer's labeling). Actively manage modifiable cardiac risk factors (smoking, hypertension, diabetes, dyslipidemia, obesity) before initiating treatment (ASCO [Armenian 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Premedication/prophylaxis:</i> Daunorubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]). Ensure adequate hydration and consider use of antihyperuricemic prophylaxis in patients at risk for tumor lysis syndrome.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b0a6d83-a7ac-4bd2-8948-9f49f264da2d">Acute lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CALGB 8811 regimen:</i> Induction: <b>IV:</b> 45 mg/m<sup>2</sup> (in patients &lt;60 years of age) or 30 mg/m<sup>2</sup> (in patients ≥60 years of age) on days 1, 2, and 3 (Course I; 4 week cycle), in combination with cyclophosphamide, prednisone, vincristine, and an asparaginase product (Larson 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CCG 1961:</i> Adults ≤21 years of age: <b>IV:</b> Induction: 25 mg/m<sup>2</sup> once weekly for 4 weeks (in combination with vincristine, prednisone, and asparaginase) (Nachman 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GRAALL-2005:</i> Adults ≤60 years of age: <b>Note:</b> Rituximab is included if CD20-positive (Huguet 2018; Maury 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: <b>IV: </b>50 mg/m<sup>2</sup> on days 1, 2, and 3 <b>and</b> 30 mg/m<sup>2</sup> on days 15 and 16 (in combination with prednisone, vincristine, asparaginase, cyclophosphamide, and G-CSF support) (Huguet 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">Late intensification: <b>IV: </b>30 mg/m<sup>2</sup> on days 1, 2, and 3 <b>and</b> on days 15 and 16 (in combination with prednisone, vincristine, asparaginase, cyclophosphamide, and G-CSF support) (Huguet 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>MRC UKALLXII/ECOG E2993:</i> Adults &lt;60 years of age:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction (Phase I): <b>IV: </b>60 mg/m<sup>2</sup> on days 1, 8, 15, and 22 (in combination with vincristine, asparaginase, and prednisone) (Rowe 2005).</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation (Cycle 3): <b>IV</b>: 25 mg/m<sup>2</sup> on days 1, 8, 15, and 22 (in combination with cyclophosphamide, cytarabine, and thioguanine) (Rowe 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>PETHEMA ALL-96:</i> Adults ≤30 years of age:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: <b>IV: </b>30 mg/m<sup>2</sup> on days 1, 8, 15, and 22 (in combination with vincristine, prednisone, asparaginase, and cyclophosphamide) (Ribera 2008).</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation-2/Reinduction: <b>IV: </b>30 mg/m<sup>2</sup> on days 1, 2, 8, and 9 (in combination with vincristine, dexamethasone, asparaginase, and cyclophosphamide) (Ribera 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Protocol 8707:</i> Adults ≤60 years of age: <b>IV:</b> Induction and Consolidation 2A cycles: 60 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with vincristine, prednisone, and an asparaginase product). An additional 60 mg/m<sup>2</sup> daunorubicin dose may be administered on day 15 of induction if bone marrow biopsy on day 14 shows residual disease (Linker 2002).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0616790-4d1f-431a-acc0-3bce79aef7bb">Acute myeloid leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CCG 2891:</i> Adults &lt;21 years of age:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: <b>IV:</b> 20 mg/m<sup>2</sup>/day continuous infusion on days 0 to 4 and 10 to 14 (in combination with dexamethasone, cytarabine, thioguanine, and etoposide) (Woods 1996).</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation: <b>IV:</b> 20 mg/m<sup>2</sup>/day continuous infusion on days 0 to 4 and 10 to 14 (in combination with dexamethasone, cytarabine, thioguanine, and etoposide) (Woods 1996).</p>
<p style="text-indent:-2em;margin-left:4em;">Cytarabine/daunorubicin (7 + 3): Induction: <b>IV:</b> 60 to 90 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with cytarabine); if residual disease was observed on day 12 to day 14 bone marrow biopsy, 45 mg/m<sup>2</sup> for 3 days as a second induction course was administered (in combination with cytarabine) (Fernandez 2009; Lowenberg 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">Cytarabine/daunorubicin (5 + 2): Consolidation/re-induction (postremission): <b>IV:</b> 45 mg/m<sup>2</sup> on days 1 and 2 (in combination with cytarabine) for 2 courses (Wiernik 1992).</p>
<p style="text-indent:-2em;margin-left:4em;">Gemtuzumab ozogamicin/cytarabine/daunorubicin (CD33-positive AML): Adults 50 to 70 years of age:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: <b>IV:</b> 60 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with cytarabine and gemtuzumab ozogamicin); if &gt;10% persistent leukemic blasts observed at day 15 bone marrow biopsy, a second induction course of 60 mg/m<sup>2</sup>/day for 2 days (in combination with cytarabine and G-CSF support) was administered (Castaigne 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation: <b>IV:</b> 60 mg/m<sup>2</sup> on day 1 of consolidation course 1 and 60 mg/m<sup>2</sup> on days 1 and 2 of consolidation course 2 (in combination with cytarabine and gemtuzumab ozogamicin) (Castaigne 2012). Refer to protocol for dosage modification details.</p>
<p style="text-indent:-2em;margin-left:4em;">Midostaurin/cytarabine/daunorubicin<i> (FLT3</i> mutated AML): Adults &lt;60 years of age: Induction: <b>IV:</b> 60 mg/m<sup>2</sup> on days 1, 2, and 3 (in combination with cytarabine and midostaurin) for 1 or 2 cycles (Stone 2017). Refer to protocol for dosage modification details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f133373-607c-467b-8bff-de6df2e90e5c">Acute promyelocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute promyelocytic leukemia (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Induction: Adults: <b>IV:</b> 50 mg/m<sup>2</sup> on days 3, 4, 5, and 6 (in combination with ATRA [tretinoin] and cytarabine) (Powell 2010) <b>or</b> 60 mg/m<sup>2</sup> on days 3, 4, and 5 (in combination with ATRA and cytarabine) (Ades 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Consolidation: Adults: <b>IV:</b> 50 mg/m<sup>2</sup> on days 1, 2, and 3 for 2 cycles (in combination with ATRA; arsenic trioxide was administered for 2 cycles prior to daunorubicin and ATRA) (Powell 2010) <b>or</b> 60 mg/m<sup>2</sup> on days 1, 2, and 3 during cycle 1 of consolidation (in combination with cytarabine), followed by 45 mg/m<sup>2</sup> on days 1, 2, and 3 during cycle 2 of consolidation (in combination with cytarabine) (Ades 2008).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991687"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Significant kidney function impairment may result in increased toxicities.</p>
<p style="text-indent:-2em;margin-left:2em;">S<sub>cr</sub> &gt;3 mg/dL: Administer 50% of normal dose (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to 50 mL/minute: Administer 75% of original dose (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Administer 50% of original dose (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Administer 50% of original dose (Krens 2019).</p></div>
<div class="block doha drugH1Div" id="F50989001"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Significant hepatic function impairment may result in increased toxicities.</p>
<p style="text-indent:-2em;margin-left:2em;">Serum bilirubin 1.2 to 3 mg/dL: Administer 75% of dose (Floyd 2006; Krens 2019; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Serum bilirubin &gt;3 mg/dL: Administer 50% of dose (Krens 2019; manufacturer's labeling), although some sources recommend avoiding daunorubicin use with serum bilirubin &gt;5 mg/dL (Floyd 2006).</p></div>
<div class="block doo drugH1Div" id="F57298610"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p></div>
<div class="block dot drugH1Div" id="F58277948"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiotoxicity:</b> Assess the benefits vs risks of continued daunorubicin treatment if patients develop signs of cardiotoxicity. Consider dexrazoxane (if appropriate) to reduce cardiac toxicity in patients who have received a high cumulative dose of anthracycline therapy (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Asymptomatic cardiac dysfunction:</i> Consider initiating heart failure medications (eg, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and/or beta-blockers) in patients with asymptomatic (stage B) heart disease (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">Mild cardiac dysfunction: Continue treatment with close cardiovascular monitoring (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate cardiac dysfunction: Interrupt treatment and utilize a multidisciplinary approach when deciding if/when to restart (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symptomatic cardiac dysfunction:</i> Initiate heart failure medications (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">Mild cardiac dysfunction: Consider a multidisciplinary approach for decisions regarding treatment interruption versus continuation (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate cardiac dysfunction: Interrupt treatment; consider a multidisciplinary approach for decisions regarding treatment reinitiation (ESC [Lyon 2022]). <i></i></p>
<p style="text-indent:-2em;margin-left:6em;">Severe cardiac dysfunction: Discontinue anthracycline therapy (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">Also refer to protocol and/or study reference for specific dosage adjustment details.</p></div>
<div class="block doe drugH1Div" id="F157122"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Cardiotoxicity may be more frequent in older adults. Use caution in patients who have inadequate bone marrow reserves due to age.</p></div>
<div class="block dop drugH1Div" id="F157142"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13207" href="/d/html/13207.html" rel="external">see "Daunorubicin: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase; refer to individual protocols. In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra caution to verify dosing parameters during calculations.</p>
<p style="text-indent:0em;margin-top:2em;">Daunorubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]; POGO [Paw Cho Sing 2019]).</p>
<p style="text-indent:0em;margin-top:2em;">Monitor cumulative anthracycline dose (combined); the risk for cardiomyopathy increases as the cumulative anthracycline dose increases (<span style="text-decoration: underline">&gt;</span>250 mg/m<sup>2</sup> of doxorubicin isotoxic equivalent dose in pediatric patients &lt;18 years and 550 mg/m<sup>2</sup> of doxorubicin isotoxic equivalent dose in patients ≥18 years); also dependent on other/additional risk factors (eg, chest irradiation); interpatient variability exists (eg, some patients may experience left ventricular dysfunction at lower doses). To calculate doxorubicin equivalent dose of daunorubicin, multiply total daunorubicin dose by 0.5 (COG 2018; ESC [Zamorano 2016]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc96c63d-34bf-4494-9bfd-412032036264">Acute lymphocytic leukemia, B-cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia, B-cell (B-ALL):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AALL0232 </i>(Larsen 2016): High risk, newly diagnosed:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Induction: IV: 25 mg/m<sup>2</sup>/dose once weekly for 4 weeks (in combination with intrathecal cytarabine, vincristine, prednisone/dexamethasone [age-dependent], pegaspargase, and intrathecal methotrexate).</p>
<p style="text-indent:-2em;margin-left:8em;">Extended induction: IV: 25 mg/m<sup>2</sup>/dose once on day 1 (in combination with vincristine, prednisone/dexamethasone [age-dependent], and pegaspargase).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Memorial Sloan Kettering-New York IIB Protocol</i> (Steinherz 1993): High risk, newly diagnosed:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Induction: IV: 60 mg/m<sup>2</sup>/<b>day</b> as a continuous infusion over 24 hours on days 0 and 1 for a total dose of 120 mg/m<sup>2</sup> (in combination with cyclophosphamide, vincristine, prednisone, pegaspargase, and intrathecal methotrexate).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance I: IV: 20 mg/m<sup>2</sup>/<b>day</b> as a continuous infusion over 24 hours on days 40 and 41 for a total dose of 40 mg/m<sup>2</sup> (in combination with prednisone, mercaptopurine, cyclophosphamide, methotrexate, vincristine, cytarabine, thioguanine, and intrathecal methotrexate). Repeat for a total of 5 cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GRAALL-2003</i> (Huguet 2009):</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥15 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Induction: IV: 50 mg/m<sup>2</sup>/dose on days 1, 2, and 3 <b>and</b> 30 mg/m<sup>2</sup> on days 15 and 16 (in combination with prednisone, vincristine, asparaginase, cyclophosphamide, and G-CSF support).</p>
<p style="text-indent:-2em;margin-left:8em;">Late intensification: IV: 30 mg/m<sup>2</sup>/dose on days 1, 2, and 3 (in combination with prednisone, vincristine, asparaginase, cyclophosphamide, and G-CSF support).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>MRC UKALLXII/ECOG E2993</i> (Rowe 2005):</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥15 years: Induction (Phase I): IV: 60 mg/m<sup>2</sup>/dose on days 1, 8, 15, and 22 (in combination with vincristine, asparaginase, and prednisone).</p>
<p style="text-indent:-2em;margin-left:4em;">PETHEMA ALL-96 (Ribera 2008):</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥15 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Induction: IV: 30 mg/m<sup>2</sup>/dose on days 1, 8, 15, and 22 (in combination with vincristine, prednisone, asparaginase, and cyclophosphamide).</p>
<p style="text-indent:-2em;margin-left:8em;">Consolidation-2/Reinduction: IV: 30 mg/m<sup>2</sup>/dose on days 1, 2, 8, and 9 (in combination with vincristine, dexamethasone, asparaginase, and cyclophosphamide).</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Remission induction:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;2 years or BSA &lt;0.5 m<sup>2</sup>: IV: 1 mg/<b>kg</b>/dose on day 1 every week for up to 4 to 6 cycles (in combination with vincristine and prednisone).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents ≥2 years and BSA ≥0.5 m<sup>2</sup>: IV: 25 mg/m<sup>2</sup>/dose on day 1 every week for up to 4 to 6 cycles (in combination with vincristine and prednisone).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b198bfa-612d-4c6f-858a-183f554dd548">Acute lymphoblastic leukemia, T-cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, T-cell (T-ALL):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AALL0434</i> (Winter 2018): Newly diagnosed: Children and Adolescents: Induction: IV: 25 mg/m<sup>2</sup>/dose on days 1, 8, 15, 22 (in combination with vincristine, prednisone, pegaspargase, intrathecal methotrexate, and cytarabine).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="783ba5d6-8d0f-4e90-b470-88de613f5f40">Acute myelogenous leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myelogenous leukemia (AML):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AAML0531</i> (Burnett 2013; Gamis 2014): Newly diagnosed:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Some aspects of protocol dosing based on previous reports (Cooper 2012; Gibson 2011; Guest 2014; Woods 1990).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children with BSA &lt;0.6 m<sup>2</sup>: Induction I and Induction II: IV: 1.67 mg/<b>kg</b>/dose on days 1, 3, 5 (in combination with cytarabine and etoposide).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents with BSA ≥0.6 m<sup>2</sup>: Induction I and Induction II: IV: 50 mg/m<sup>2</sup>/dose on days 1, 3, and 5 (in combination with cytarabine and etoposide).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AAML0431 </i>(Taub 2017): Patients with Down syndrome &lt;4 years of age at time of AML diagnosis:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children ≤3 years: Induction I, III, and IV: IV: 0.67 mg/<b>kg</b>/<b>day</b> as a continuous infusion on days 1 to 4 (96 hours total) (in combination with cytarabine and thioguanine).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;3 to &lt;4 years: Induction I, III, and IV: IV: 20 mg/m<sup>2</sup>/<b>day</b> as a continuous infusion on days 1 to 4 (96 hours total) (in combination with cytarabine and thioguanine).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090528"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer's labeling recommends the following adjustment: All patients: SCr &gt;3 mg/dL: Administer 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been recommended (Aronoff 2007):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis/continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose.</p></div>
<div class="block dohp drugH1Div" id="F51090529"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer's labeling recommends the following adjustments: All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 1.2 to 3 mg/dL: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin &gt;3 mg/dL: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been recommended based on experience from adult patients (Floyd 2006): All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 1.2 to 3 mg/dL: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 3.1 to 5 mg/dL: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin &gt;5 mg/dL: Avoid use.</p></div>
<div class="block adr drugH1Div" id="F157087"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac failure (dose-related, may be delayed for 7 to 8 years after treatment), ECG abnormality (transient, generally asymptomatic and self-limiting; includes atrial premature contractions, ST segment changes on ECG, supraventricular tachycardia, ventricular premature contractions)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (reversible)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (mild), stomatitis, vomiting (mild)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Red urine discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression (onset: 7 days; nadir: 10 to 14 days; recovery: 21 to 28 days; primarily leukopenia; anemia, thrombocytopenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Radiation recall phenomenon</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Discoloration of sweat</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, discoloration of saliva, gastrointestinal ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Post-injection flare</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Discoloration of tears</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, cardiac arrhythmia, cardiomyopathy, hepatitis, hypersensitivity reaction (systemic; includes angioedema, dysphagia, dyspnea, pruritus, urticaria), increased serum bilirubin, increased serum transaminases, infertility, injection site reaction (includes injection site cellulitis, local thrombophlebitis, pain at injection site), leukemia (secondary), myocardial infarction, myocarditis, nail bed changes (pigmentation), nail disease (banding), onycholysis, pericarditis, skin rash, sterility, typhlitis (neutropenic)</p></div>
<div class="block coi drugH1Div" id="F157101"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to daunorubicin or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Patients who exhibit myocardial lesions or those ≥75 years of age.</p></div>
<div class="block war drugH1Div" id="F157084"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Daunorubicin may cause severe bone marrow suppression at therapeutic doses; may lead to infection or hemorrhage. Use with caution in patients with drug-induced bone marrow suppression (preexisting), unless the therapy benefit outweighs the toxicity risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiomyopathy: Daunorubicin may cause cumulative, dose-related myocardial toxicity; may lead to heart failure. May occur either during treatment or may be delayed (months to years after cessation of treatment). According to the manufacturer's labeling, the incidence of myocardial toxicity increases as the total cumulative (lifetime) doses approach 550 mg/m<sup>2</sup> in adults, 400 mg/m<sup>2</sup> in adults receiving chest radiation, 300 mg/m<sup>2</sup> in children &gt;2 years of age, or 10 mg/kg in children &lt;2 years of age. Total cumulative dose should take into account prior treatment with other anthracyclines or anthracenediones, previous or concomitant treatment with other cardiotoxic agents or irradiation of chest. Although the risk increases with cumulative dose, irreversible cardiotoxicity may occur at any dose level. Patients with preexisting heart disease, hypertension, concurrent administration of other antineoplastic agents, prior or concurrent chest irradiation, advanced age; and infants and children are at increased risk.</p>
<p style="text-indent:-2em;margin-left:6em;">- According to American Society of Clinical Oncology guidelines (ASCO [Armenian 2017]), the risk of cardiac dysfunction is increased with high-dose anthracycline therapy (eg, equivalent to doxorubicin ≥250 mg/m<sup>2</sup>); high-dose radiotherapy (≥30 Gy) with the heart in the treatment field; lower-dose anthracyclines (eg, equivalent to doxorubicin &lt;250 mg/m<sup>2</sup>) in combination with lower-dose radiotherapy (&lt;30 Gy) with the heart in the treatment field; lower-dose anthracyclines AND any of the following risk factors: ≥2 cardiovascular risk factors (including smoking, hypertension, diabetes, dyslipidemia, and obesity) during or after completion of therapy or age ≥60 years at cancer treatment, or compromised cardiac function (eg, borderline low LVEF [50% to 55%], history of myocardial infarction, moderate or higher valvular heart disease) before or during treatment; treatment with lower-dose anthracycline followed by trastuzumab (sequential therapy); other risk factors for anthracycline-induced cardiotoxicity include age ≥60 years at time of treatment and 2 or more cardiovascular risk factors (smoking, hypertension, diabetes, dyslipidemia, or obesity) during or after treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; if extravasation occurs, severe local tissue damage leading to ulceration and necrosis, and pain may occur. For IV administration only. Daunorubicin is NOT for IM or SUBQ administration. Administer through a rapidly flowing IV line. Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Secondary leukemias may occur when used with combination chemotherapy or radiation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: May cause tumor lysis syndrome and hyperuricemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Cardiotoxicity may occur more frequently in older adults. Use with caution in patients with impaired renal function and/or poor marrow reserve due to advanced age; dosage adjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Infants and children are at increased risk for developing delayed cardiotoxicity; long-term periodic cardiac function monitoring is recommended. A panel from the American Society of Pediatric Hematology/Oncology (ASPHO) and International Society of Pediatric Oncology (SIOP) recommends in favor of an anthracycline infusion duration of at least 1 hour in pediatric patients to reduce the potential for cardiotoxicity (ASPHO/SIOP [Loeffen 2018]). However, extravasation risks should also be minimized and the protocol infusion duration specified in a protocol should be followed, particularly if the patient is receiving dexrazoxane as a cardioprotectant.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation recipients: Use with caution in patients who have received radiation therapy; reduce dosage in patients who are receiving radiation therapy simultaneously.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878408"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric patients are at increased risk for developing delayed cardiac toxicity and congestive heart failure during early adulthood due to an increasing census of long-term survivors; risk factors include: Young treatment age (&lt;5 years), cumulative exposure, and concomitant cardiotoxic therapy. Up to 40% of pediatric patients may have subclinical cardiac dysfunction and 5% to 10% may develop heart failure. Long-term monitoring is recommended for all pediatric patients (COG 2018).</p></div>
<div class="block foc drugH1Div" id="F157095"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/4 mL (4 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/4 mL (4 mL)</p></div>
<div class="block geq drugH1Div" id="F157080"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323094"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (DAUNOrubicin HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/4 mL (per mL): $39.34 - $40.24</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866527"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cerubidine: 20 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F157098"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Daunorubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">IV: For IV administration only. Do not administer IM or SubQ. Administer as slow IV push over 1 to 5 minutes into the tubing of a rapidly infusing IV solution of D5W or NS or may dilute further and infuse over 15 to 30 minutes.</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dexrazoxane or dimethyl sulfate [DMSO]). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (Perez Fidalgo 2012); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dexrazoxane:</i> 1,000 mg/m<sup>2</sup> (maximum dose: 2,000 mg) IV (administer in a large vein remote from site of extravasation) over 1 to 2 hours days 1 and 2, then 500 mg/m<sup>2</sup> (maximum dose: 1,000 mg) IV over 1 to 2 hours day 3; begin within 6 hours of extravasation. Day 2 and day 3 doses should be administered at approximately the same time (± 3 hours) as the dose on day 1 (Mouridsen 2007; Perez Fidalgo 2012). <b>Note:</b> Reduce dexrazoxane dose by 50% in patients with moderate to severe renal impairment (CrCl &lt;40 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DMSO:</i> Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (Perez Fidalgo 2012).</p></div>
<div class="block admp drugH1Div" id="F52612486"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Daunorubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]; POGO [Paw Cho Sing 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administration rate/technique may vary by protocol. May administer IV push over 1 to 15 minutes into the tubing of a rapidly infusing IV solution of D5W or NS. Some pediatric protocols use a continuous infusion of the daily dose over 24 hours. Drug is very irritating, do not inject IM or SUBQ. Refer to individual protocol for details, particularly if the patient is receiving dexrazoxane as a cardioprotectant (including timing with respect to dexrazoxane administration); take precautions to minimize extravasation risks.</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dimethyl sulfate [DMSO] or dexrazoxane [adult]) (see Management of Drug Extravasations for more details). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (Pérez Fidalgo 2012); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p></div>
<div class="block hazard drugH1Div" id="F49130969"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F157096"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia:</b> Treatment (remission induction) of acute lymphocytic leukemia (ALL) in children and adults (in combination with other chemotherapy).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia:</b> Treatment (remission induction) of acute myeloid leukemia (AML) in adults (in combination with other chemotherapy).</p></div>
<div class="block off-label drugH1Div" id="F58277893"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute lymphocytic leukemia, consolidation or late intensification phases; Acute myeloid leukemia, consolidation phase</p></div>
<div class="block mst drugH1Div" id="F157169"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DAUNOrubicin may be confused with DACTINomycin, DAUNOrubicin liposomal, DOXOrubicin, DOXOrubicin liposomal, epiRUBicin, IDArubicin, valrubicin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9837877"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F157089"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ado-Trastuzumab Emtansine: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with ado-trastuzumab emtansine should avoid anthracycline-based therapy for up to 7 months after stopping ado-trastuzumab emtansine.  Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bevacizumab: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fam-Trastuzumab Deruxtecan: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with fam-trastuzumab deruxtecan should avoid anthracycline-based therapy for up to 7 months after stopping fam-trastuzumab deruxtecan. Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Margetuximab: Anthracyclines may enhance the adverse/toxic effect of Margetuximab. Specifically, the risk of cardiac dysfunction may be increased.  Management: Avoid anthracycline-based therapy for up to 4 months after discontinuing margetuximab due to an increased risk of cardiac dysfunction. If anthracyclines must be used with margetuximab monitor cardiac function closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taxane Derivatives: May enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue. Management: Consider separating doxorubicin and paclitaxel administration by as much time as possible, using liposomal doxorubicin or epirubicin instead of doxorubicin, or using docetaxel instead of paclitaxel. Monitor closely for cardiovascular and other toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trastuzumab: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab.  Monitor closely for cardiac dysfunction in patients receiving anthracyclines with trastuzumab.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49297798"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients should avoid becoming pregnant during therapy. In general, patients who could become pregnant should use effective contraception during systemic anticancer therapy and for 3 to 6 months after the last dose. Patients with partners who could become pregnant should use effective contraception during treatment and for 3 to 6 months after the last dose of systemic anticancer therapy (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">Daunorubicin is associated with an intermediate risk of azoospermia and infertility in males (ESMO [Lambertini 2020]). Recommendations are available for fertility preservation of male and female patients to be treated with anticancer agents (ASCO [Oktay 2018]; Klipstein 2020).</p></div>
<div class="block pri drugH1Div" id="F157103"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Daunorubicin crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Based on data from animal reproduction studies, in utero exposure to daunorubicin may cause fetal harm. Outcome data following maternal use of daunorubicin during pregnancy are available (Fracchiolla 2017; NTP 2013).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach (ESMO [Peccatori 2013]). Guidance is available for the management of acute myeloid leukemia during pregnancy. If daunorubicin is indicated, it should not be administered in the first trimester, but may begin in the second trimester; use between 24 and 32 weeks gestation should consider benefits and risks of therapy (BSH [Ali 2015]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F21121942"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if daunorubicin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during daunorubicin therapy.</p></div>
<div class="block mop drugH1Div" id="F157093"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor cumulative (lifetime) anthracycline/daunorubicin dose. CBC with differential and platelets (at baseline and frequently during treatment), LFTs (at baseline), kidney function tests (at baseline), and serum uric acid levels. Monitor ECG and obtain LVEF (echocardiography [ECHO] or multigated radionuclide angiography [MUGA] scan) at baseline and periodically. Monitor for signs/symptoms of tumor lysis syndrome; monitor for secondary malignancies. Monitor infusion site for signs/symptoms of extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Additional cardiovascular monitoring (ASCO [Armenian 2017], ESC [Lyon 2022]):</i> Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking. Echocardiogram (transthoracic preferred, perform at baseline and 12 months after therapy completion for all patients; in addition, perform every 2 cycles and within 3 months after therapy completion for high- or very high-risk patients). Cardiac biomarkers (troponin and natriuretic peptide at baseline for high and very high-risk patients [may consider for low- and moderate-risk]; also prior to each cycle during anthracycline treatment and at 3 and 12 months after therapy completion for high- and very high-risk patients). In patients who develop signs/symptoms of cardiac dysfunction during therapy, an echocardiogram is recommended for diagnostic workup; if echocardiogram is not available or feasible, a cardiac MRI (preferred) or MUGA scan may be utilized; obtain serum cardiac biomarkers. Refer to a cardiologist when clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F157083"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Daunorubicin inhibits DNA and RNA synthesis by intercalation between DNA base pairs and by steric obstruction. Daunomycin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA.</p></div>
<div class="block phk drugH1Div" id="F157100"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Distributes widely into tissues, particularly the liver, kidneys, lung, spleen, and heart; does not distribute into the CNS</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily hepatic to daunorubicinol (active), then to inactive aglycones, conjugated sulfates, and glucuronides</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Initial: 45 minutes; Terminal: 18.5 hours; Daunorubicinol plasma half-life: ~27 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (40%); urine (~25% as unchanged drug and metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F157104"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Daunorubicin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina | Daunogobbi | Daunorubicina gp pharm | Daunorubicina kemex | Maxidauno</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Daunorubicin | Daunoxome</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina | Evoclass</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunoblastin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunorubicina | Daurocina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina | Daunorubicin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Al dauno | Cerubidine | Daunac | Daunorubicina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunoblastina</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastin | Daunorubicin | Daunoxome</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Daunorubicin | Daunorubicina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunoblastin | Daunoblastina | Daunocyte | Daunorubicin | Daunosin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Daunocin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Daunoplus</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cerubidin | Daunoxome</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunorubicine Dci | Daunoxome</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cerubidin | Daunorubicin | Daunoxome | Trav daunorubicin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Rubomycin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina | Daunocin | Daunorubicin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cerubidin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Dauneon | Daunocin | Daunomycin | Daunorubitec | Daunotec | Zedaunor</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina | Daunorubicina | Daunoxome</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Daunomycin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Ckd daunorubicin | Daunoblastina | Daunocin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunoblastina</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunoblastina</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Daunorubicina | Rubilem | Runabicon</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina | Daunocin | Daunorubicin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cerubidin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Daunorubicin | Daunorubicin Pfizer</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Daunorubicina</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">D-blastin | Daunoblastina | Daunocin | Rubilem</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunoblastin | Daunocin | Daunomicina | Daunotec | Daunoxome</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunorubicin | Daunorubicin HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunoblastina | Daunorrubicina</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine | Daunorubicin lens | Daunoxome | Rubomycin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cerubidin | Cerubidine</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cerubidine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Daunomicina | Daunosin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina | Daunomycin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastina | Rubomycin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Daunorrubicina FU</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Daunoblastin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Daunorubicin HCL</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17975017">
<a name="17975017"></a>Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. <i>Blood</i>. 2008;111(3):1078-1084.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/17975017/pubmed" id="17975017" target="_blank">17975017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26081614">
<a name="26081614"></a>Ali S, Jones GL, Culligan DJ, Marsden PJ, Russell N, Embleton ND, Craddock C; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. <i>Br J Haematol</i>. 2015;170(4):487-495. doi:10.1111/bjh.13554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/26081614/pubmed" id="26081614" target="_blank">26081614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th Ed. American College of Physicians; 2007:98.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23940227">
<a name="23940227"></a>Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. <i>J Clin Oncol</i>. 2013;31(27):3360-3368. doi:10.1200/JCO.2012.47.4874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/23940227/pubmed" id="23940227" target="_blank">23940227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22482940">
<a name="22482940"></a>Castaigne S, Pautas C, Terré C, et al; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. <i>Lancet</i>. 2012;379(9825):1508-1516. doi:10.1016/S0140-6736(12)60485-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/22482940/pubmed" id="22482940" target="_blank">22482940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cerubidine.1">
<a name="Cerubidine.1"></a>Cerubidine (daunorubicin) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; October 2022.</div>
</li>
<li>
<div class="reference">
                  Children's Oncology Group (COG). Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf. Updated October 2018. Accessed March 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21766293">
<a name="21766293"></a>Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. <i>Cancer</i>. 2012;118(3):761-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/21766293/pubmed" id="21766293" target="_blank">21766293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3555940">
<a name="3555940"></a>Crom WR, Glynn-Barnhart AM, Rodman JH, et al. Pharmacokinetics of Anticancer Drugs in Children. <i>Clin Pharmacokinet</i>. 1987;12(3):168-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/3555940/pubmed" id="3555940" target="_blank">3555940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2033963">
<a name="2033963"></a>Cuttner J, Mick R, Budman DR, et al. Phase III Trial of Brief Intensive Treatment of Adult Acute Lymphocytic Leukemia Comparing Daunorubicin and Mitoxantrone: A CALGB Study. <i>Leukemia</i>. 1991;5(5):425-431.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/2033963/pubmed" id="2033963" target="_blank">2033963</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Daunorubicin [prescribing information]. Bedford, OH: Bedford Laboratories; June 2013.</div>
</li>
<li>
<div class="reference">
                  Daunorubicin [prescribing information]. Bridgewater, NJ: Hisun Pharmaceuticals; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L. Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients. <i>Pediatr Blood Cancer</i>. 2011;57:191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19776406">
<a name="19776406"></a>Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. <i>N Engl J Med</i>. 2009;361:1249-1259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/19776406/pubmed" id="19776406" target="_blank">19776406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of Chemotherapy. <i>Semin Oncol</i>. 2006;33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of Cancer Therapy. <i>J Clin Oncol</i>. 2005;23(30):7685-7696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28645262">
<a name="28645262"></a>Fracchiolla NS, Sciumè M, Dambrosi F, et al. Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature. <i>BMC Cancer</i>. 2017;17(1):442. doi:10.1186/s12885-017-3436-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/28645262/pubmed" id="28645262" target="_blank">28645262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25092781">
<a name="25092781"></a>Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. <i>J Clin Oncol</i>. 2014;32(27):3021-3032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/25092781/pubmed" id="25092781" target="_blank">25092781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21902686">
<a name="21902686"></a>Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. <i>Br J Haematol</i>. 2011;155(3):366-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/21902686/pubmed" id="21902686" target="_blank">21902686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Guest.2014">
<a name="Guest.2014"></a>Guest EM, Aplenc R, Sung L, et al. Gemtuzumab ozogamicin (GO) in infants with acute myeloid leukemia (AML) - combined results from the Children's Oncology Group (COG) trials. AAML03P1 and AAML0531. <i>Blood</i>. 2014;124:377.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update.<i> J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29863974">
<a name="29863974"></a>Huguet F, Chevret S, Leguay T, et al; Group of Research on Adult ALL (GRAALL). Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial.<i> J Clin Oncol.</i> 2018;36(24):2514-2523. doi:10.1200/JCO.2017.76.8192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/29863974/pubmed" id="29863974" target="_blank">29863974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19124805">
<a name="19124805"></a>Huguet F, Lequay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. <i>J Clin Oncol</i>. 2009;27:911-918.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/19124805/pubmed" id="19124805" target="_blank">19124805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Keefe DL. Anthracycline-Induced Cardiomyopathy. <i>Semin Oncol</i>. 2001;28(4)(suppl 12):2-7.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32071259">
<a name="32071259"></a>Klipstein S, Fallat ME, Savelli S; Committee on Bioethics; Section on Hematology/Oncology; Section on Surgery. Fertility preservation for pediatric and adolescent patients with cancer: medical and ethical considerations. <i>Pediatrics</i>. 2020;145(3):e20193994. doi:10.1542/peds.2019-3994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/32071259/pubmed" id="32071259" target="_blank">32071259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32976936">
<a name="32976936"></a>Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. <i>Ann Oncol</i>. 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/32976936/pubmed" id="32976936" target="_blank">32976936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27114587">
<a name="27114587"></a>Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: A report from Children's Oncology Group Study AALL0232. <i>J Clin Oncol</i>. 2016;34(20):2380-2388. doi:10.1200/JCO.2015.62.4544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/27114587/pubmed" id="27114587" target="_blank">27114587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7718875">
<a name="7718875"></a>Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. <i>Blood</i>. 1995;85:2025-2037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/7718875/pubmed" id="7718875" target="_blank">7718875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12011123">
<a name="12011123"></a>Linker C, Damon L, Ries C, et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2002;20:2464-2471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/12011123/pubmed" id="12011123" target="_blank">12011123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29077260">
<a name="29077260"></a>Loeffen EAH, van Dalen EC, Mulder RL, et al; Anthracycline Cardiotoxicity Working Group. The duration of anthracycline infusion should be at least one hour in children with cancer: A clinical practice guideline. <i>Pediatr Blood Cancer.</i> 2018;65(2). doi:10.1002/pbc.26867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/29077260/pubmed" id="29077260" target="_blank">29077260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19776405">
<a name="19776405"></a>Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. <i>N Engl J Med</i>. 2009;361:1235-1248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/19776405/pubmed" id="19776405" target="_blank">19776405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8916311">
<a name="8916311"></a>Masaoka T, Ogawa M, Yamada K, et al. A Phase II Comparative Study of Idarubicin Plus Cytarabine Versus Daunorubicin Plus Cytarabine in Adult Acute Myeloid Leukemia. <i>Semin Hematol</i>. 1996;33(4)(suppl 3):12-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/8916311/pubmed" id="8916311" target="_blank">8916311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27626518">
<a name="27626518"></a>Maury S, Chevret S, Thomas X, et al; for GRAALL. Rituximab in B-lineage adult acute lymphoblastic leukemia. <i>N Engl J Med</i>. 2016;375(11):1044-1053. doi:10.1056/NEJMoa1605085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/27626518/pubmed" id="27626518" target="_blank">27626518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17185744">
<a name="17185744"></a>Mouridsen HT, Langer SW, Buter J, et al. Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies. <i>Ann Oncol</i>. 2007;18(3):546-550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/17185744/pubmed" id="17185744" target="_blank">17185744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24736875">
<a name="24736875"></a>National Toxicology Program (NTP). NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. <i>NTP Monogr</i>. 2013;(2):i-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/24736875/pubmed" id="24736875" target="_blank">24736875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620997">
<a name="29620997"></a>Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/29620997/pubmed" id="29620997" target="_blank">29620997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):S160-S170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20705755">
<a name="20705755"></a>Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i>. 2010;116:3751-3757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/20705755/pubmed" id="20705755" target="_blank">20705755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18398150">
<a name="18398150"></a>Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. <i>J Clin Oncol</i>. 2008;26:1843-1849.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/18398150/pubmed" id="18398150" target="_blank">18398150</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16105981">
<a name="16105981"></a>Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. <i>Blood</i>. 2005;106:3760-3767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/16105981/pubmed" id="16105981" target="_blank">16105981</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Speth PA, Minderman H, Haanen C. Idarubicin v Daunorubicin: Preclinical and Clinical Pharmacokinetic Studies. <i>Semin Oncol</i>. 1989;16(1)(suppl 2):2-9.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8221579">
<a name="8221579"></a>Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. <i>Cancer</i>. 1993;72(10):3120-3130. doi:10.1002/1097-0142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/8221579/pubmed" id="8221579" target="_blank">8221579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28644114">
<a name="28644114"></a>Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. <i>N Engl J Med</i>. 2017;377(5):454-464. doi:10.1056/NEJMoa1614359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/28644114/pubmed" id="28644114" target="_blank">28644114</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Taub JW, Berman JN, Hitzler JK, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. <i>Blood</i>. 2017;129(25):3304-3313. doi:10.1182/blood-2017-01-764324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/28389462/pubmed" id="28389462" target="_blank">28389462</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8874180">
<a name="8874180"></a>Weick JK, Kopecky KJ, Appelbaum FR, et al. A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study. <i>Blood</i>. 1996;88(8):2841-2851.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/8874180/pubmed" id="8874180" target="_blank">8874180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1730080">
<a name="1730080"></a>Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. <i>Blood</i>. 1992;79(2):313-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/1730080/pubmed" id="1730080" target="_blank">1730080</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Winter SS, Dunsmore KP, Devidas M, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. <i>J Clin Oncol</i>. 2018;36(29):2926-2934. doi:10.1200/JCO.2018.77.7250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/30138085/pubmed" id="30138085" target="_blank">30138085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8652810">
<a name="8652810"></a>Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children’s Cancer Group. <i>Blood</i>. 1996;87:4979-4989.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/8652810/pubmed" id="8652810" target="_blank">8652810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2205352">
<a name="2205352"></a>Woods WG, Ruymann FB, Lampkin BC, et al. The Role of Timing of High-Dose Cytosine Arabinoside Intensification and of Maintenance Therapy in the Treatment of Children With Acute Nonlymphocytic Leukemia. <i>Cancer</i>. 1990;66(6):1106-1113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/2205352/pubmed" id="2205352" target="_blank">2205352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27567406">
<a name="27567406"></a>Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2016;37(36):2768-2801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daunorubicin-drug-information/abstract-text/27567406/pubmed" id="27567406" target="_blank">27567406</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9326 Version 329.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
